Zevra Therapeutics Partners with Orsini for Enhanced Distribution of OLPRUVA® (Sodium Phenylbutyrate) for Urea Cycle Disorders
Celebration, Fla. and Elk Grove Village, Ill. June 18, 2024’ - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), an innovative pharmaceutical company dedicated to developing and commercializing transformative therapies for patients, and Orsini Specialty Pharmacy (Orsini), a market-leading independent provider of specialty pharmacy care, proudly announce that Orsini is now designated as the specialty pharmacy partner for the distribution and patient support of OLPRUVA® (sodium phenylbutyrate) for oral suspension. This proactive collaboration aims to streamline access to OLPRUVA® for patients and healthcare providers, ensuring optimal management for those affected by certain urea cycle disorders (UCDs).
About OLPRUVA® (Sodium Phenylbutyrate)
OLPRUVA® is a prescription medication meticulously engineered to assist in the long-term management of UCDs, which include deficiencies in specific enzymes such as carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS). These enzyme deficiencies are critical components of the urea cycle, a vital biochemical pathway responsible for removing ammonia from the bloodstream. UCDs are rare genetic disorders that can lead to potentially life-threatening buildups of ammonia in the blood, necessitating continuous and meticulous management.
OLPRUVA® works alongside other therapies, including dietary modifications, to help control and reduce the levels of ammonia in the blood, providing a crucial therapeutic option for both adult and pediatric patients suffering from these challenging conditions.
The Partnership with Orsini Specialty Pharmacy
Orsini Specialty Pharmacy, renowned for its exceptional specialty pharmacy care and patient support services, will facilitate the distribution of OLPRUVA®. This partnership ensures that patients receive not only their medication but also comprehensive support including education, adherence programs, and coordination with healthcare providers. The goal is to enhance the overall treatment experience for patients and caregivers, reducing the burden of managing complex and chronic conditions like UCDs.
Enhanced Patient Support and Services
The transition to Orsini as the specialty pharmacy provider promises to bring a myriad of benefits, including:
- ’Personalized Patient Care’: Orsini will offer individualized support to patients, including education on medication use and lifestyle adjustments necessary to manage UCD symptoms effectively.
- ’Medication Management Programs’: These programs will ensure that patients adhere to their medication regimens, minimizing the risk of complications and improving health outcomes.
- ’Seamless Coordination with Healthcare Providers’: Orsini’s integrated services will allow for better communication and coordination between patients, pharmacists, and healthcare providers, ensuring that therapy is always optimized and any issues are swiftly addressed.
Accessing OLPRUVA® Prescribing Information
For healthcare professionals and patients seeking detailed guidance, OLPRUVA®’s full prescribing information is accessible via the following link: OLPRUVA-Prescribing-Information.pdf (olpruva.com)(https://www.globenewswire.com/Tracker’data=MuQNMo1IQKgRs4hRaMVINnCs9hw8Arn3JvrsrwCKtBsZP9dDBBA87jZMUf8egX-xOCe9UzJ3GrT7pR69n6rxd_q_JFq8CVK_5bfliQFQBU7LF7MPhIvg77tY1-Avx9_yldtoTAozK3OCsKSwzG6_x_QKwyRxMNKrbs0HBj5NesObuDXP0BOc_CPCzkuFD_GDmasFbjV69ynpFgq1CSxnTQ==).
Importance of This Partnership
This strategic alliance between Zevra Therapeutics and Orsini Specialty Pharmacy underscores the commitment of both organizations to improving the lives of patients with rare conditions. By leveraging Orsini’s expertise in specialty pharmacy services and Zevra’s innovative therapies, the partnership aims to provide unmatched support for those living with UCDs, ensuring that life-changing treatments like OLPRUVA® are accessible and managed with the highest standards of care.
About Zevra Therapeutics’
Zevra Therapeutics, Inc. is a forward-thinking biopharmaceutical company focused on developing and delivering transformative therapies to improve the lives of patients with serious and rare diseases. The company is committed to innovation, driven by a robust pipeline of pharmaceuticals designed to address unmet medical needs.
About Orsini Specialty Pharmacy’
Orsini Specialty Pharmacy is a premier independent specialty pharmacy providing comprehensive clinical and distribution services for patients with rare and complex conditions. Orsini’s patient-centric approach ensures that individuals receive the best possible care and support throughout their treatment journey.
Comments